33 research outputs found
European Lung Cancer Working Party Clinical Practice Guidelines. Small Cell Lung Cnacer: IV. Limited disease
Get PDFThe present guidelines on the management of limited disease small cell lung cancer (SCLC) were formulated by the ELCWP in April 2007. They are designed to answer the following seven questions: 1) What is the definition of limited disease? 2) Should chest radiotherapy be provided and what are the benefits? 3) What is the optimal timing and mode of administration of chest irradiation? 4) Which are the optimal radiotherapy parameters: dose, fractionation, target volume? 5) What is the optimal chemotherapy regimen for limited disease SCLC? 6) Should prophylactic cranial irradiation be provided, when and for which patients? 7) What is the additional role of thoracic surgery in early SCLC
The role of cisplatin in the treatment of small-cell lung cancer
No full text(editorial)SCOPUS: ed.jinfo:eu-repo/semantics/publishe
Combination chemotherapy with mitomycin and vindesine in advanced non-small cell lung cancer: A pilot study by the lung cancer working party (Belgium)
No full textSCOPUS: ar.jinfo:eu-repo/semantics/publishe
A phase II randomised trial comparing the cisplatin-etoposide combination chemotherapy with or without carboplatin as second-line therapy for small-cell lung cancer
No full textSCOPUS: ar.jinfo:eu-repo/semantics/publishe
67O ARE FIRST-LINE PLATINUM-BASED (PT) REGIMENS IMPROVING SURVIVAL IN COMPARISON WITH NON-PLATINUM (NPT) CHEMOTHERAPY (CT) IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)? A META-ANALYSIS (MA) OF RANDOMISED TRIALS
No full textA three-arm phase III randomised trial comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV non-small-cell lung cancer
No full textFragile histidine triad protein expression in nonsmall cell lung cancer and correlation with Ki-67 and with p53
No full text
Causes of death in febrile granulocytopenic cancer patients receiving empiric antibiotic therapy
No full text
